The Battle with COVID-19: Insight on External Intervention and Future Vaccination

Main Article Content

Ashraf S. Hakim
Sohier M. Syame
Mohamed M. Shehata
Ahmed Taha A. Sayed

Abstract

The battle against the pandemic novel coronavirus infection (namely COVID-19) that gravely hurts human health is a global mission for all humanity. Currently, there are no specific COVID-19 therapies; immune-suppressors as corticosteroids, protease inhibitor antivirals, monoclonal antibody analogues as well as prospective plasma therapy. Because of the possible adverse effects and continuous emerging doubts about the drugs combating COVID-19; certain medicinal plants and dietary herbs are potentially used to prevent or cure COVID-19. Nowadays investigations and clinical trials focused on development of safe and effective either drugs or vaccines to control even stop COVID-19 in near future. Providing comprehensive spotlights on virus pathogenesis, host cell interaction, immunological response, potential therapy, and vaccine emergence for COVID-19 is discussed in this article.

Keywords:
COVID-19, COVID-19 drug therapy, COVID-19 immunotherapy, COVID-19 natural therapy, COVID-19 vaccines.

Article Details

How to Cite
Hakim, A. S., Syame, S. M., Shehata, M. M., & Sayed, A. T. A. (2020). The Battle with COVID-19: Insight on External Intervention and Future Vaccination. South Asian Journal of Research in Microbiology, 7(2), 46-61. https://doi.org/10.9734/sajrm/2020/v7i230169
Section
Review Article

References

Srnivasia RB, Srini VK, Anavaj S, et al. Adjunct immunotherapies for the management of severely Ill COVID-19 patients. Cell Reports Medicine. 2020;1(2): 100016.

Suraphan P, Chi-Tang H, Lee-Yan Sheen. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. J Tradit Complement, Med; 2020.

Yuefei J, Haiyan Y, Wangquan J, et al. Virology, epidemiology, pathogenesis and control of COVID-19. Viruses. 2020;12(4): 372.

Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 2011;7:349-359.

Perez EE, Orange JS, Bonilla F, et al. Mar Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1-S46.

Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease. Open Forum Infect. Dis. 2020;7:102.

Xie Y, Cao S, Li Q, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J. Infect; 2020.

DOI: 10.1016/j.jinf.2020;03.044

Shao Sr Z, Feng Y, Zhong L, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study. Med Rxiv; 2020.

DOI: 10.1101/2020;.04.11.20061739

Recent open-label trials were conducted and reported benefits of IVIG therapy in severe SARS-CoV-2-induced pneumonia.

Available:https://clinicaltrials.gov/ct2/show/NCT04261426

Long Q, Liu H-J, Deng K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020;26:845–848.

Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. Emerg. Infect. Dis. 2020;26(7):1478-1488.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with (2019) novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.

Bao L, Deng W, Gao H, et al. Reinfection could not occur in SARS CoV-2 infected rhesus macaques. Bio Rxiv; 2020.

DOI: 10.1101/2020;03.13.990226.

Chen X, Li R, Pan Z, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17:647–649.

FDA Approved Drug Products: Dexamethasone Injection.

Acailable:https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/40572s002lbledt.pdf

Wilson JF, Corticosteroids. In: Wilson JF, (Eds). Drugs eicosanoids. Immunoassay Kit Directory (Series A: Clinical Chemistry). vol 1 / 3 / 4. Springer, Dordrecht; 1995.

Loew D, Schuster O, and Graul EH. Dose-dependent pharmacokinetics of dexamethasone. Eur J Clin Pharmacol. 1986;30(2):225-30.

Spoorenberg SM, Deneer VH, Grutters JC, et al. Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol. 2014;78(1):78-83.

Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism in vitro: Species differences. J Steroid Biochem Mol Biol. 1997;62(4):345-52.

Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013;4(Suppl 1):S94-8.

Available:https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19

Ben-Zvi I, Kivity S, Langevitz P, et al. Hydroxychloroquine: From malaria to autoimmunity. Clinic Rev Allerg Immunol. 2012;42:145–153.

McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. The American Journal of Medicine. 1983;75(1A):11–18.

Boelaert JR, Piette J, Sperber K. The potential place of chloroquine in the treatment of HIV-1-infected patients. J Clin Virol. 2001;20:137-140.

Mizui T, Yamashina S, Tanida I, et al. Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol. 2010;45:195-20.

Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013;23:300-302.

Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454.

Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal. 2005;2(1):69.

Mauthe M, Orhon I, Rocchi C, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435– 1455.

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? International Journal of Antimicrobial Agents. Advance Online Publication. 2020;55(5):105938.

Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323:264–8.

Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology journal. 2005;2(1):69.

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269-271.

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bio Science Trends. 2020;16;14(1):72-73.

Alexander Y, Charlotte Y, and Bing Y. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19. Medical Hypotheses. 2020;144:109802. Advance Online Publication.

Walker O, Birkett DJ, Alvan G, et al. Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol. 1983;15:375-377.

Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996;31(4):257-74.

Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 5 Suppl. 1996;1:S11-5.

Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: A physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018;365(3):447-459.

Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: A new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015;9(1):79-81.

Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019;32(2):176-186.

Baranovich T, Wong SS, Armstrong J, et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 2013;87:3741–3751.

Furuta Y, Komeno T, and Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy, Series B. 2017;93(7):449-463.

Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. Med Rxiv. Preprint posted; 2020.

Available:https://clinicaltrials.gov/ct2/show/NCT04336904?term=NCT04336904&draw=2&rank=1

Available:https://clinicaltrials.gov/ct2/show/NCT04358549?term=NCT04358549&draw=2&rank=1

Available:https://clinicaltrials.gov/ct2/show/NCT04346628?term=NCT04346628&draw=2&rank=1

Nguyen TH, Guedj J, Anglaret X, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017;23;11(2):e0005389.

Madelain V, Nguyen TH, Olivo A, et al. Ebola virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 2016;55(8):907-23.

Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report; 2020.

Sidwell, Robert W, et al. Broad-spectrum antiviral activity of virazole: 1-β-D-Ribofuranosyl-1,2,4-Triazole-3- Carboxamide. Science. New Series. 1972; 177(4050):705–6.

Streeter DG, Witkowski JT, Khare GP, et al. Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. USA. 1973;70:1174–1178.

Krilov LR. Respiratory syncytial virus: Update on infection, treatment and prevention. Curr Infect Dis Rep. 2001;3:242-246.

Van Voris LP, Newell PM. Antivirals for the chemoprophylaxis and treatment of influenza. Semin Respir Infect. 1992;7:61-70.

Andrei G, De Clercq E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993;22:45-75.

Leyssen P, Balzarini J, de Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 2005;79:1943–1947.

Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006;16:37–48.

Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother. 1989;33: 2009-2011.

FDA Approved Drug Products: Rebetol (ribavirin) oral capsules; 2020.

Alberici F, Delbarba E, Manent C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int; 2020.

Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects. PLoS Med. 2006;3(9):e343.

Morra ME, VanThanh L, Kamel MG, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis. Rev Med Virol. 2018;28(3): e1977.

Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: A multi center observational study. Clin Infect Dis. Published on line; 2019.

FDA Approved Drug Products: Rebetol (ribavirin) oral capsules; 2020.

Altınbas S, Holmes JA, Altınbas A. Hepatitis C virus infection in pregnancy: An update. Gastroenterol Nurs. 2020;43(1): 12-21.

Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281–93.

Shuter J. Lopinavir/Ritonavir in the treatment of HIV-1 Infection: A review. Therapeutics and Clinical Risk Management. 2008;4:1023–33.

Boffito M, Arnaudo I, Raiteri R, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS. 2002;16(15):2081‐2083.

Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS‐CoV. Nat Commun. 2020;11(1): 222.

Nukoolkarn V, Lee VS, Malaisree M, et al. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS‐CoV3CL (pro) inhibitors. J Theor Biol. 2008;254(4):861‐867.

Zhang XW, Yap YL. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem. 2004;12(10):2517‐2521.

Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:81.

Available:https://pubmed.ncbi.nlm.nih.gov/?term=Lopinavir Ritonavir+AND+covid

Crommentuyn KML, Mulder JW, Mairuhu ATA. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1 infected patients. Antivir Ther. 2004;9:779–85.

Yilmaz A, Stahle L, Hagberg L, et al. Cerebrospinal fl uid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ ritonavir regimen. Scand J Infect Dis. 2004;36:823–8.

Letendre SL, van der Brande G, Hermes A, et al. Lopinavir and ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis. 2007;45:1511–7.

Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs and humans. Pharm Res. 2004;21:1622–30.

FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for Oral Use.

Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.

Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9.

Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11(4):326.

Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. M Bio. 2018;9(2): e00221-18.

Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269-271.

Available:htps://www.clinicaltrials.gov/ct2/show/NCT04292899

Available:htps://www.clinicaltrials.gov/ct2/show/NCT04292730

Available:htps://clinicaltrials.gov/ct2/show/NCT04280705

Warren T, Jordan R, Lo M, et al. Nucleotide prodrug GS-5734 is a broad-spectrum flu virus inhibitor that provides complete therapeutic protection against the development of Ebola virus disease (EVD) in infected non-human primates. Nature. 2015;139(3):311–20.

Ding C, Jones G. Technology evaluation: MRA, Chugai. Curr Opin Mol Ther. 2003;5(1):64-9.

Calabrese LH, Rose-John S. IL-6 biology: Implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol. 2014;10(12):720-727.

Cellina M, Orsi M, Bombaci F, et al. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. DiagnInterv Imaging. 2020;(31)S2211-5684(20)30087-5.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA; 2020.

Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.

Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.

Cellina M, Orsi M, Bombaci F, et al. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging; 2020.

Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 Patients with Tocilizumab; 2020.

Effective treatment of severe COVID-19 patents with Tocilizumab. Available on China Xiv Website.

Available:htp://www.chictr.org.cn/showprojen.aspx?proj=49409

U.S. Natonal Library of Medicine. ClinicalTrials.gov; 2020. NLM identifier: NCT04320615.

(Accessed 2020 Apr 2)

Available:htps://clinicaltrials.gov/ct2/show/study/NCT04320615

Hoffmann F, La Roche Ltd. Roche initiates Phase III clinical trial of Actemra /RoActemra in hospitalized patients with severe COVID-19 pneumonia [Press release]. Basel, Switzerland. Roche; 2020.

Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507.

Abdallah H, Hsu JC, Lu P, et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57(4):459-468.

FDA Approved Drug Products: Actemra Tocilizumab Intravenous or Subcutaneous Injection.

Bian H, Zheng ZH, Wei D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv; 2020.

Wang Ning, Jian Shang, Shibo Jiang, Lanying Du. Subunit vaccines against emerging pathogenic human corona viruses. Frontiers in Microbiology. 2020;11:298.

Du L, Wanbo T, Yusen Z, Shibo J. Vaccines for the prevention against the threat of MERS-CoV. Expert Review of Vaccines. 2016;15(9):1123-1134.

Zhou Y, Shibo J, Lanying D. Prospects for a MERS-CoV spike vaccine. Expert Review of Vaccines. 2018;17(8):677-686.

Reham A, Muhammad A, Zenebech W, et al. Investigations of a possible chemical effect of Salvadora persica chewing sticks. Evidence-Based Complementary and Alternative Medicine. 2017;10. Article ID: 2576548.

Mabberley DJ. Mabberley’s plant-book: A portable dictionary of plants, their classification and uses. Cambridge University Press, NewYork, NY, USA, 3rd Edn; 2008.

Muhammad ZA, Gokhan Z, Mohamad FMA. A review of the traditional and modern uses of Salvadora persica L. (Miswak): Toothbrush tree of Prophet Muhammad. Journal of Ethno-pharmacology. 2018;213:409-444.

Taha MYM. Antiviral effect of ethanolic extract of Salvadora Persica (Siwak) on herpes simplex virus infection. Al–Rafidain Dent J. 2008;8(1):50–55.

Owis AI, et al. Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease. RSC Advances. 2020;10(33): 19570–75.

Darmani H, Al-Hiyasat A, Elbetieha A, Alkofahi A. The effect of an extract of Salvadora persica (Meswak, chewing stick) on fertility of male and female mice. Phytomedicine. 2003;10(1):63–65.

Vellingiri, Balachandar, et al. COVID-19: A promising cure for the global panic. Science of the Total Environment. 2020;725:138277.

Yang Y, et al. Traditional chinese medicine in the treatment of patients infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. International Journal of Biological Sciences. 2020;16(10):1708–17.

Shahid MA, Mohammad AC, Mohammod AK. Scope of natural plant extract to deactivate COVID-19; 2020. In Review. Preprint.

Available:https://www.researchsquare.com/article/rs-19240/v1

Deng-hai Z, et al. Silico screening of chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. Journal of Integrative Medicine. 2020;18(2):152–58.

Mohammad T. Nigella sativa seeds: Folklore treatment in modern day medicine. Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association. 2008;14(3):105–6.

Mohsen A, et al. Traditional effects of medicinal plants in the treatment of respiratory diseases and disorders: An ethnobotanical study in the Urmia, Asian Pacific Journal of Tropical Medicine. 2014;7:S364–68.

Mohaddese M. Natural therapeutic approach of Nigella sativa (Black Seed) fixed oil in management of sinusitis. Integrative Medicine Research. 2018;1:27–32.

Ebrahim M, et al. Nigella sativa L. (Black Cumin): A promising natural remedy for wide range of illnesses, evidence-based. Complementary and Alternative Medicine; 2019.

Hakim AS, Abouelhag HA, Abdou AM, et al. Assessment of immunomodulatory effects of black cumin seed (Nigella sativa) extract on macrophage activity in vitro. Inter J Vet Sci. 2019;8(4):385-389.

RCSB PDB - 6LU7: The crystal structure of COVID-19 main proteasein complex with an Inhibitor N3; 2020.

Bouchentouf S, Noureddine M. Identification of compounds from Nigella sativa as new potential inhibitors of 2019 novel Coronasvirus (Covid-19): Molecular docking study. Preprint; 2020.

A spotlight on chemical constituents and pharmacological activities of Nigella glandulifer Freynet Sint Seed; 2020.

Available:http://dx.doi.org/10.1155/2013/820183

Morales Soto F, Thompson. Thyme: The Genus Thymus. In Thyme: The Genus Thymus; 2002.

Böhme K, Barros-Velázquez J, Calo-Mata P, Aubourg SP. Antibacterial, antiviral and antifungal activity of essential oils: Mechanisms and applications. In T. G. Villa and P. Veiga-Crespo (Eds.), Antimicrobial Compounds. Springer Berlin Heidelberg. 51-81.

Nolkemper S, Reichling J, Stintzing FC, et al. Antiviral effect of aqueous extracts from species of the Lamiaceae family against Herpes simplex virus type 1 and type 2 in vitro. Planta Med, 2006;72(15):1378-82.

Behravan J, Ramezani M, Nobandegani EF, Gharaee E. Antiviral and antimicrobial activity of Thymus transcaspicus essential oil. Pharmacology Online. 2011;1:1190-1199.

Astani A, Reichling J, Schnitzler P. Comparative study on the antiviral activity of selected monoterpenes derived from essential oils. Phytother Res. 2010;24(5): 673-9.

Morales Stahl-Biskup, Sáez Soto F, Thompson Venskutonis. Thyme. The Genus Thymus. In Thyme: The Genus Thymus; 2002.

Altman RD, Marcussen KC. Effects of ginger extract on knee pain in patients with osteoarthritis. International Journal of Arthritis and Rheumatism. 2001;44(11): 246–2462.

Chrubasik S, Pittler MH, Roufogalis BD, Zingiberis rhizoma: A comprehensive review on the ginger effect and efficacy profiles. Phytomedicine. 2005;12:684–701.

Denyer CV, Jackson P, Loakes DM, et al. Isolation of anti-rhinoviral-sesquiterpenes from ginger (Zingiber officinale). Journal of Natural Products. 1994;57:658–662.

Sookkongwaree K, Geitmann M, Roengsumran S, et al. Inhibition of viral proteases by Zingiberaceae extracts and flavones isolated from Kaempferia parviflora. Pharmazie. 2006;61:717–721.

Schnitzler P, Koch C, Reichling J. Susceptibility of drug-resistant clinical herpes simplex virus type 1 strains to essential oils of ginger, thyme, hyssop and sandalwood. Antimicrobial Agents and Chemotherapy. 2007;51:1859–1862.

Koch C, Reichling J, Schneele J, Schnitzler P. Inhibitory effect of essential oils against herpes simplex virus type 2. Phytomedicine. 2008;15:71–78.

Idang EO, Yemitan OK, Mbagwu HOC, Udom GJ, Ogbuagu EO, Udobang JA. Toxicological assessment of Zingiber officinale roscoe (Ginger) root oil extracts in albino rats; 2019.

Hussain J, Rehman N, Shinwari ZK, et al. Preliminary comparative analysis of four botanicals used in the traditional medicines of Pakistan. Pak. J. Bot. 2014;46(4):1403-1407.

Al-Juhaimi YF. Citrus fruits by products as source of bioactive compounds with antioxidant potential. Pak J. Bot. 2014;46(4):1459-1462.

Özcan MM, Chalchat CJ. Chemical composition and antifungal effect of anise (Pimpinella anisum L.) fruit oil at ripening stage. Ann. Microbiol. 2006;56:353-358.

Tirapelli CR, Andrade RC, de Cassano OA, et al. Antispasmodic and relaxant effects of the hydroalcoholic extract of Pimpinella anisum (Apiaceae) on rat anococcygeous smooth muscle. J. Enthopharmacol. 2007;110:23-29.

Ozguven M. Aniseed. Handbook of Herbs and Spices. (2nd Ed.). 2012;2138-150.

Ompal S, Zakia K, Neelam M, Manoj KS. Chamomile (Matricaria chamomilla L.): An overview. Pharmacogn Rev. 2011;5(9):82–95.

Issac O. 1st Ed. Czecho-Slovakia: Prague press. Recent progress in chamomile research- medicines of plant origin in modern therapy; 1989.

Schilcher H, Kamille D.1st Ed. Germany: Wissenschaft Verlagsgesellschaft. Handbuch fur arzte, apotheker und and erenaturwissenschaftler; 1987.

Shoara R, Hashempur MH, Ashraf A, et al. Aug of topical Matricaria chamomilla L. (chamomile) oil for knee osteoarthritis: A randomized controlled clinical trial. Complement Ther Clin Pract. 2015;21(3): 181-7.

Mbaveng AT, Kuete V. Chapter 17 - Cinnamon species, victor kuete, medicinal spices and vegetables from africa, academic press. 2017;385-395.

Fatima M, Zaidi NSS, Amraiz D, Afzal F. In Vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza A virus. Journal of Microbiology and Biotechnology. 2016;26(1):151–159.

Garg R. Nutraceuticals in glucose balance and diabetes. In, Nutraceuticals Efficacy, Safety and Toxicity, Academic Press. 2016;145–60.

Graham RL, Donalds EF, Baric RS. A decade after SARS: Strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 2013;11:836-848.

Dae-Gyun A, Hye-Jin S, Mi-Hwa K, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19) clover biopharmaceuticals vaccines programs. J. Microbiol. Biotechnol. 2020;30(3):313–324.

CEPI. GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus; 2020.

(Accessed 28 Feb. 2020)

Available:https://www.gsk.com/en-gb/media/pressreleases/cepi-and-gsk-announce-collaboration-to-strengthenthe-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus/

Significant step’ in COVID-19 vaccine quest.

(Accessed 28 Feb. 2020)

Available:https://www.uq.edu.au/news/article/2020/02/significantstep%E2%80%99-covid-19-vaccine-quest

Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800.

(Accessed 03 Mar. 2020)

Available:http://ir.inovio.com/news-andmedia/news/press-release-details/2020/Inovio-AcceleratesTimeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx.

Inovio’ sproduc pipeline.

(Accessed 28 Feb. 2020)

Available:https://www.inovio.com/product-pipeline. dMAb Technology platform

(Accessed 28 Feb. 2020)

Available:https://www.inovio.com/technology#dmab

mRNA platform: Enabling Drug Discovery and Development.

(Accessed 28 Feb. 2020)

Available:https://www.modernatx.com/mrna-technology/mrna-platform-enabling-drug-discovery-development

hyFc platform.

(Accessed 20 Feb. 2020)

Available:http://www.genexine.com/ m21.php

Available:https://clinicaltrials.gov/ct2/show/NCT04345419

Available:https://clinicaltrials.gov/ct2/show/NCT04354805

Available:https://clinicaltrials.gov/ct2/show/NCT04345406

Available:https://clinicaltrials.gov/ct2/show/NCT04350931

Available:https://clinicaltrials.gov/ct2/show/NCT04353180

Available:https://clinicaltrials.gov/ct2/show/NCT04353180

Available:https://clinicaltrials.gov/ct2/show/NCT04353336

Available:https://clinicaltrials.gov/ct2/show/NCT04323345

Available:https://clinicaltrials.gov/ct2/show/NCT04349241

Available:https://clinicaltrials.gov/show/NCT04351295

Available:https://clinicaltrials.gov/show/NCT04376788

Available:https://clinicaltrials.gov/show/NCT04374591

Available:https://clinicaltrials.gov/show/NCT04360122

Available:https://clinicaltrials.gov/show/NCT04368923

Available:https://clinicaltrials.gov/show/NCT04357028

Available:https://clinicaltrials.gov/show/NCT04347876

Available:https://clinicaltrials.gov/show/NCT04348877

Available:https://clinicaltrials.gov/show/NCT04348214